Market Intelligence, Clinical Progress, and High-Purity Reagents for Serine Pathway Inhibition.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PHGDH drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PHGDH Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic assays and biophysical binding screening. |
View PHGDH Products |
| Gene Delivery | PHGDH Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and target overexpression validation. |
View PHGDH Products |
| Benchmark Ab | Anti-PHGDH Recombinant Antibody Recombinant positive control antibody for Western Blot, IHC, and ELISA validation. |
View PHGDH Products |
| Validator | PHGDH siRNA Set Target-specific gene knockdown for functional validation and specificity controls. |
View PHGDH Products |
| Related Target A | PSAT1 Phosphoserine aminotransferase 1; downstream enzyme in the phosphorylated pathway of serine biosynthesis. |
View PSAT1 Products |
| Related Target B | PSPH Phosphoserine phosphatase; catalyzes the final step of the serine biosynthesis pathway. |
View PSPH Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against other dehydrogenases | High-purity recombinant PHGDH along with a counter-screening panel of homologous dehydrogenases, strictly verified by mass spectrometry. |
| High-throughput screening (HTS) compatibility | Sequence-verified, active-grade recombinant proteins with batch-to-batch consistency and optimized storage buffers to maintain enzymatic stability. |
| Lack of Controls | Clinical benchmark antibodies and validated positive controls integrated into the workflow. |
| False Positives | Validated siRNA sets included for orthogonal target knockdown and specificity confirmation. |
Live PHGDH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PHGDH therapeutics is intensifying, with major players shifting focus from traditional orthosteric inhibitors to allosteric inhibitors and targeted protein degraders (PROTACs). As first-generation metabolic therapies reach the clinic, the next wave of R&D is targeting the serine synthesis pathway (SSP) to overcome resistance to standard chemotherapies and targeted agents in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Academic Spin-offs, Biotech | Triple-Negative Breast Cancer (TNBC), Melanoma | High-purity active enzyme for enzymatic assays and SPR/MST biophysical binding validation. |
| PROTAC (Degrader) | Targeted Protein Degradation Pioneers | NSCLC, Solid Tumors | Recombinant PHGDH with specific affinity tags (His/GST) to validate ternary complex formation. |
| RNAi / Therapeutics | RNAi Therapeutics Developers | Metabolic Disorders, Oncology | Validated siRNA and Lentiviral vectors for robust target knockdown in cell-based assays. |